QRG Capital Management Inc. Has $2.14 Million Holdings in Haleon plc (NYSE:HLN)

QRG Capital Management Inc. grew its stake in shares of Haleon plc (NYSE:HLN) by 20.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,934 shares of the company’s stock after acquiring an additional 34,884 shares during the period. QRG Capital Management Inc.’s holdings in Haleon were worth $2,136,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Janney Montgomery Scott LLC raised its position in shares of Haleon by 182.3% in the first quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company’s stock valued at $3,726,000 after buying an additional 283,410 shares in the last quarter. Manning & Napier Advisors LLC acquired a new stake in shares of Haleon in the second quarter valued at approximately $2,833,000. First Eagle Investment Management LLC raised its position in shares of Haleon by 31.0% in the first quarter. First Eagle Investment Management LLC now owns 1,361,021 shares of the company’s stock valued at $11,555,000 after buying an additional 321,928 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in shares of Haleon by 25.1% in the first quarter. Orion Portfolio Solutions LLC now owns 694,524 shares of the company’s stock valued at $5,897,000 after buying an additional 139,263 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Haleon by 79.1% in the first quarter. Sei Investments Co. now owns 781,089 shares of the company’s stock valued at $6,632,000 after buying an additional 345,036 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HLN shares. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Berenberg Bank initiated coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Stock Performance

NYSE HLN opened at $9.60 on Friday. The firm’s fifty day moving average price is $10.21 and its two-hundred day moving average price is $9.29. The stock has a market cap of $43.43 billion, a PE ratio of 28.22, a PEG ratio of 2.93 and a beta of 0.30. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.